|
Published by: Decision Resources
Published: Feb. 16, 2007 - 42 Pages The price of this report has been reduced due to its age. The original price was $3,700 for PDF.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- The Prognosis for 2007
- Current Climate of Public Distrust
- PricewaterhouseCoopers Survey
- Credibility of the Pharmaceutical Industry
- Barrie G. James, Ph.D., Pharma Strategy Consulting
- Positive Industry Dynamics
- Inlicensing Technology and Late-Stage Products
- Demand Is Driving Cost
- Diversifi ed Offerings vs. Targeted Ones
- Inventing and Marketing New Diseases
- Expected New Products and the Impact of Patent Expiries
- Emerging 2007 Blockbusters and Near Blockbusters
- Januvia
- Galvus
- Acomplia
- Invega
- Pristiq
- Succinobucol
- Cimzia
- RSD-1235
- Increasing Development Costs and Pipeline Issues
- Patent Expiries
- Harsher Legislative and Regulatory Climates in the United States
- Patent Litigation Settlements and Patent Reform Legislation
- Paul King, M.S., J.D., Member of the District of Columbia Bar, KING PLLC, Capitol Hill
- Patent Litigation Settlements
- Patent Reform Legislation
- Prescription Drug User Fee Act
- Increasing Potential for U.S. Drug Price Regulation
- Access to Life-Saving Medicines Act
- Setting the Stage for Universal Health Care Debate in 2008
- The Pharmaceutical Industry vs. the Judiciary
- Paul King, M.S., J.D., Member of the District of Columbia Bar, KING PLLC, Capitol Hill
- What Makes Teva So Successful?
- The Road to Success
- A Generics Powerhouse
- An Innovator to Watch
- The Road Ahead
- Biogenerics Move on Stage
- Europe Makes the First Move
- John Ansell, M.A., John Ansell Consultancy
- The United States Hesitates
- Biogenerics Forecast, 2005-2015
- Rewards for Innovation-Blessing or Curse for the European Pharmaceutical Industry?
- Neil Grubert, M.A., Program Manager, Spectrum, Pharmacoeconomics, Pricing, and Reimbursement
- Lost Advantage
- Government Initiatives
- Harmonization of Health Technology Assessments
- Industry Frustration
- Premiums for Innovation
- SPECTRUM Pharmaceutical Industry Dynamics 1-3
- 2007 State of Industry
- Press Date: February 14, 2007 Decision Resources, Inc.
- 2007 Landscape for Japan's Pharmaceutical Industry
- Hiroshi Tashiro, M.Sc., Research Manager of Decision Resources' Tokyo office
- Growth in the Japanese Pharmaceutical Market
- Outlook for the Japanese Generics Market
- Revision of Corporate Laws
- China-A Developing Pharmaceutical Market
- Why China? Why Now?
- Lin (Victor) Li, Analyst, and Alice von Loesecke, Ph.D., Senior Director-New Products,
- Decision Resources
- Health Care Reform
- State Food and Drug Administration Initiatives
- Growth Drivers
- Potentially Huge Drug Markets
- Near-Term Opportunities
- Outlook
- Appendix
- Figures
- 1. The Downward Trend in Perceptions of the Pharmaceutical Industry in the United States, 1997-2005
- 2. Inlicensing Activities of the Top 20 Pharma Companies, 2006
- 3. Increasing Costs of Licensing Deals, 1996 to Mid 2006
- 4. Research and Development Expenses, Total NDAs, and NDAs for NME Submissions, 1993-2004
- 5. Blockbusters Facing Patent Expiry in 2007 (with 2005 Sales)
- 6. Competitive Positions in the Multiple Sclerosis Market, 2005 and 2010
- 7. Timeline of Biogenerics Commercialization Milestones
- 8. U.S. and European (G5) Brand and Biogeneric Markets: Four Major Biologic Classes, 2005-2015
- 9. Size of the Japanese Pharmaceutical Market, 2002-2005
- 10. Brazil, Russia, India, and China Populations and Gross Domestic Product, 2005
- 11. High-Growth Developing Pharmaceutical Markets in China
- Tables
- 1. Disconnect Between Public and Industry Perceptions of Pharmaceutical Companies, 2007
- 2. Development Status and Anticipated Launch Year of Emerging Blockbusters
- 3. Teva's Pipeline of Innovative Drugs by Phase and Therapeutic Area Focus
- 4. Select Biogenerics Under Development, 2006
- 5. Consolidated Sales of Top Ten Japanese Pharmaceutical Companies, Fiscal Year Ended March 2006
- 6. Sales of the Four Largest Domestic Generics Manufacturers in Japan, Fiscal Year Ended March 2006
- 7. Multinational Companies Selling Leading Drugs in Select Chinese Markets
AbstractThe innovator pharmaceutical industry will face many challenges in 2007. Key among them will be repairing its tarnished reputation, the growth of the generic drug industry, and the impact of the newly elected Democratic Congress. In this report, we examine these and other challenges the industry will face, the evolving strategies of generics company Teva, the launch of biogenerics into European markets, the growing acceptance of generic drugs in Japan, and opportunities for pharmaceutical companies in China.
Get the Answers You Need to Shape Your Strategy
Many new drugs are set to launch in 2007.
What are they, and what is their sales potential?
Legislators, the judiciary, and industry are trying to strike a balance between the needs of innovator companies and generics companies and those of health care consumers and payers.
What industry business practices is the legislature planning to address in 2007?
Despite the many challenges that the pharmaceutical industry faces today, there remain areas of significant opportunity.
What are they, and how best can industry take advantage of them?
Teva is fast becoming one of the most successful pharmaceutical companies in the world.
What has been its strategy for success, and what is in its future?
Multinational pharmaceutical corporations (MPCs) are positioning themselves to benefit from the powerful growth engines known as BRIC (Brazil, Russia, India, and China). China holds the leading position in pharmaceutical market potential over Brazil, Russia, and India.
What makes China so attractive to MPCs?
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
